Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03987685 · ClinicalTrials.gov registry record · Phase 1
Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
A Phase 1 study, sponsored by Athenex.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03987685 is a Phase 1 study that has completed, run by Athenex. The registered enrollment target is 10 participants.
The verdict
NCT03987685, a Phase 1 study, has completed, sponsored by Athenex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a multicenter, nonrandomized, open-label, safety, tolerability and pharmacokinetic (PK) study to determine the MTD and optimal dosing of Oratopo. No control group has been included.
Interventions
- DRUG Oratopo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-07-19 |
| Est. Completion | 2021-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03987685
The ClinicalTrials.gov registry entry for NCT03987685 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Athenex, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oratopo is the first listed.
NCT03987685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03987685 about?
NCT03987685 is a clinical study titled "Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies". This is a multicenter, nonrandomized, open-label, safety, tolerability and pharmacokinetic (PK) study to determine the MTD and optimal dosing of Oratopo. No control group has been included.
What is the current status of trial NCT03987685?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2018-07-19. Estimated completion is 2021-01-09.
What interventions are being tested in trial NCT03987685?
The interventions under investigation include: Oratopo (DRUG).
Who is sponsoring clinical trial NCT03987685?
This trial is sponsored by Athenex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.